Trial Profile
A Phase 1 Single-Dose, Open-label, Sequential, Three-Period Crossover Study to Evaluate the Pharmacokinetics of WD-1603 Tablets in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Feb 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Hong Kong WD Pharmaceutical
- 11 Feb 2020 Status changed from not yet recruiting to completed.
- 11 Dec 2018 New trial record